1. Home
  2. LEGN vs CMA Comparison

LEGN vs CMA Comparison

Compare LEGN & CMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • CMA
  • Stock Information
  • Founded
  • LEGN 2014
  • CMA 1849
  • Country
  • LEGN United States
  • CMA United States
  • Employees
  • LEGN N/A
  • CMA N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • CMA Major Banks
  • Sector
  • LEGN Health Care
  • CMA Finance
  • Exchange
  • LEGN Nasdaq
  • CMA Nasdaq
  • Market Cap
  • LEGN 7.0B
  • CMA 8.1B
  • IPO Year
  • LEGN 2020
  • CMA N/A
  • Fundamental
  • Price
  • LEGN $37.19
  • CMA $57.00
  • Analyst Decision
  • LEGN Strong Buy
  • CMA Hold
  • Analyst Count
  • LEGN 12
  • CMA 24
  • Target Price
  • LEGN $79.50
  • CMA $67.42
  • AVG Volume (30 Days)
  • LEGN 1.2M
  • CMA 1.9M
  • Earning Date
  • LEGN 03-11-2025
  • CMA 04-21-2025
  • Dividend Yield
  • LEGN N/A
  • CMA 5.07%
  • EPS Growth
  • LEGN N/A
  • CMA N/A
  • EPS
  • LEGN N/A
  • CMA 5.02
  • Revenue
  • LEGN $627,241,000.00
  • CMA $3,195,000,000.00
  • Revenue This Year
  • LEGN $121.45
  • CMA $8.17
  • Revenue Next Year
  • LEGN $65.49
  • CMA $3.50
  • P/E Ratio
  • LEGN N/A
  • CMA $11.40
  • Revenue Growth
  • LEGN 119.97
  • CMA N/A
  • 52 Week Low
  • LEGN $30.17
  • CMA $45.32
  • 52 Week High
  • LEGN $69.24
  • CMA $73.45
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 54.69
  • CMA 27.14
  • Support Level
  • LEGN $33.94
  • CMA $63.32
  • Resistance Level
  • LEGN $35.77
  • CMA $65.35
  • Average True Range (ATR)
  • LEGN 1.82
  • CMA 2.18
  • MACD
  • LEGN -0.11
  • CMA -0.94
  • Stochastic Oscillator
  • LEGN 61.16
  • CMA 12.37

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About CMA Comerica Incorporated

With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.

Share on Social Networks: